Cargando…

Usefulness of B‐Type Natriuretic Peptide for Predicting the Risk of Stroke in Patients With Heart Failure With Preserved Ejection Fraction

BACKGROUND: B‐type natriuretic peptide (BNP) is a well‐known biomarker for prognosis in heart failure with patients with preserved ejection fraction. However, the clinical predictive ability of BNP for the risk of stroke in HFpEF is not clear. METHODS AND RESULTS: A total of 799 patients with HFpEF...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xiao, Abudukeremu, Ayiguli, Yu, Peng, Cao, Zhengyu, Sun, Runlu, Wu, Maoxiong, Chen, Zhiteng, Ma, Jianyong, Zhu, Wengen, Chen, Yangxin, Zhang, Yuling, Wang, Jingfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375473/ https://www.ncbi.nlm.nih.gov/pubmed/35904188 http://dx.doi.org/10.1161/JAHA.121.024302

Ejemplares similares

U-shaped association between the triglyceride–glucose index and atrial fibrillation incidence in a general population without known cardiovascular disease
por: Liu, Xiao, et al.
Publicado: (2023)

Association of motor index scores with fall incidence among community-dwelling older people
por: Liu, Xiao, et al.
Publicado: (2022)

Liver fibrosis scores and atrial fibrillation incidence in heart failure with preserved ejection fraction
por: Liu, Xiao, et al.
Publicado: (2022)

No Sex Differences in Psychological Burden and Health Behaviors of Healthcare Workers During the COVID-19 Stay-at-Home Orders
por: Gu, Wenli, et al.
Publicado: (2021)

Patients with heart failure with preserved ejection fraction and low levels of natriuretic peptides
por: Meijers, W. C., et al.
Publicado: (2016)

Efficacy of exogenous atrial natriuretic peptide in patients with heart failure with preserved ejection fraction: deficiency of atrial natriuretic peptide and replacement therapy
por: Matsumoto, Shingo, et al.
Publicado: (2020)

Marked elevation of B-type natriuretic peptide in patients with heart failure and preserved ejection fraction
por: Tate, Samuel, et al.
Publicado: (2014)

Natriuretic Peptide Levels and Stages of Left Ventricular Dysfunction in Heart Failure with Preserved Ejection Fraction
por: Dal Canto, Elisa, et al.
Publicado: (2023)

Natriuretic Peptides in Heart Failure with Preserved Left Ventricular Ejection Fraction: From Molecular Evidences to Clinical Implications
por: Tanase, Daniela Maria, et al.
Publicado: (2019)

Natriuretic peptides for the detection of diastolic dysfunction and heart failure with preserved ejection fraction—a systematic review and meta-analysis
por: Remmelzwaal, Sharon, et al.
Publicado: (2020)

Role of natriuretic peptide receptor C signalling in obesity-induced heart failure with preserved ejection fraction with pulmonary hypertension
por: Eroume-A Egom, Emmanuel, et al.
Publicado: (2020)

Comparison of liver fibrosis scores for predicting mortality and morbidity in heart failure with preserved ejection fraction
por: Cao, Yalin, et al.
Publicado: (2023)

Weight Change and Mortality Risk in Heart Failure With Preserved Ejection Fraction
por: Huang, Peisen, et al.
Publicado: (2021)

Midregional pro-atrial natriuretic peptide is a superior biomarker to N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure patients with preserved ejection fraction
por: Cui, Kun, et al.
Publicado: (2018)

Ejection fraction, B‐type natriuretic peptide and risk of stroke and acute myocardial infarction among patients with heart failure
por: Greenberg, Barry, et al.
Publicado: (2019)

Association of Body-Weight Fluctuation With Outcomes in Heart Failure With Preserved Ejection Fraction
por: Li, Yi, et al.
Publicado: (2021)

Effects of Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction in Patients Undergoing Peritoneal Dialysis
por: Fu, Sha, et al.
Publicado: (2021)

Authors’ reply: role of natriuretic peptide receptor C signalling in obesity-induced heart failure with preserved ejection fraction with pulmonary hypertension
por: Agrawal, Vineet, et al.
Publicado: (2020)

Clinical implication of pulmonary hospitalization in heart failure with preserved ejection fraction: from the TOPCAT
por: Dong, Bin, et al.
Publicado: (2020)

Body Mass Index, Natriuretic Peptides, and Risk of Adverse Outcomes in Patients With Heart Failure and Preserved Ejection Fraction: Analysis From the TOPCAT Trial
por: Pandey, Ambarish, et al.
Publicado: (2018)

Natriuresis, Diuresis, and Volume Changes in Diabetics With Heart Failure With Preserved Ejection Fraction: Impact of Sodium‐Glucose Cotransporter 2 Inhibitors on Natriuretic Peptides
por: Silva Enciso, J.
Publicado: (2020)

Central venous pressure and acute kidney injury in critically ill patients with multiple comorbidities: a large retrospective cohort study
por: Sun, Runlu, et al.
Publicado: (2022)

Efficacy and Safety of High-Density Lipoprotein/Apolipoprotein A1 Replacement Therapy in Humans and Mice With Atherosclerosis: A Systematic Review and Meta-Analysis
por: Abudukeremu, Ayiguli, et al.
Publicado: (2021)

Prognostic significance of resting cardiac power to left ventricular mass and E/e’ ratio in heart failure with preserved ejection fraction
por: Chen, Cong, et al.
Publicado: (2022)

Heart failure with preserved ejection fraction
por: Rigolli, Marzia, et al.
Publicado: (2013)

Heart failure with preserved ejection fraction
por: ElGuindy, Ahmed, et al.
Publicado: (2012)

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2019)

Microvascular Rarefaction and Heart Failure With Preserved Ejection Fraction
por: Zeng, Heng, et al.
Publicado: (2019)

Prognostic Value of Anxiety Between Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction
por: Lin, Tin‐Kwang, et al.
Publicado: (2019)

Characteristics of acute congestive heart failure with normal ejection fraction and less elevated B-type natriuretic peptide
por: Shimamoto, Ken, et al.
Publicado: (2009)

Highest Obesity Category Associated With Largest Decrease in N‐Terminal Pro‐B‐Type Natriuretic Peptide in Patients Hospitalized With Heart Failure With Preserved Ejection Fraction
por: Vaishnav, Joban, et al.
Publicado: (2020)

Discriminative Utility of Apelin-to-NT-Pro-Brain Natriuretic Peptide Ratio for Heart Failure with Preserved Ejection Fraction among Type 2 Diabetes Mellitus Patients
por: Berezin, Alexander A., et al.
Publicado: (2022)

Natriuretic Peptide Clearance Receptor (NPR-C) Pathway as a Novel Therapeutic Target in Obesity-Related Heart Failure With Preserved Ejection Fraction (HFpEF)
por: Egom, Emmanuel Eroume A.
Publicado: (2021)

Biomarkers in heart failure with preserved ejection fraction
por: Meijers, W. C., et al.
Publicado: (2016)

Management of heart failure with preserved ejection fraction
por: Gard, Emma, et al.
Publicado: (2020)

Managing heart failure with preserved ejection fraction
por: Davidson, Alexander, et al.
Publicado: (2020)

Biomarkers in Heart Failure with Preserved Ejection Fraction
por: Bayes-Genis, Antoni, et al.
Publicado: (2022)

Comorbidities in heart failure with preserved ejection fraction
por: Deichl, Andrea, et al.
Publicado: (2022)

Personalized Management for Heart Failure with Preserved Ejection Fraction
por: Lin, Chang-Yi, et al.
Publicado: (2023)

Influence of polypharmacy on patients with heart failure with preserved ejection fraction: a retrospective analysis on adverse outcomes in the TOPCAT trial
por: Wu, Yuzhong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tdn471hdlvppmmv73d4snb69gu